ArticleBlood2010
IL-6 and MYC collaborate in plasma cell tumor formation in mice.
Article in Blood, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- When Autoimmunity Meets Malignancy: A Rare Case of Concomitant Systemic Lupus and Multiple Myeloma.Clinical case reports · 2026Article
- Targeting the Liquid-Liquid Separation Region of c-Maf for Treating Chromosomal Translocations in Multiple Myeloma.MedComm · 2025Article
- SAE1 promotes tumor cell malignancyActa pharmaceutica Sinica. B · 2025Article
- Immunocompetent mouse models of multiple myeloma.Seminars in hematology · 2025Review
- Bone marrow inflammation in haematological malignancies.Nature reviews. Immunology · 2024Review
- IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma.Haematologica · 2023Article
- Current and Future PET Imaging for Multiple Myeloma.Life (Basel, Switzerland) · 2023Review
- Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma.Blood reviews · 2022Review
- Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma.Molecular cancer therapeutics · 2022Article
- Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.Frontiers in immunology · 2021Review
- Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice.American journal of physiology. Regulatory, integrative and comparative physiology · 2019Article
- Article
- Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.International journal of molecular sciences · 2018Review
- ATP-degrading ENPP1 is required for survival (or persistence) of long-lived plasma cells.Scientific reports · 2017Article
- Proteomic Characterization of the World Trade Center dust-activated mdig and c-myc signaling circuit linked to multiple myeloma.Scientific reports · 2016Article
- Transgenic mouse model of IgMBlood cancer journal · 2016Article
- Preclinical animal models of multiple myeloma.BoneKEy reports · 2016Article
- Quantitative Expression and Co-Localization of Wnt Signalling Related Proteins in Feline Squamous Cell Carcinoma.PloS one · 2016Article
- KSHV Latency Locus Cooperates with Myc to Drive Lymphoma in Mice.PLoS pathogens · 2015Article
- IL10 receptor is a novel therapeutic target in DLBCLs.Leukemia · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Interleukin-6 (IL-6) plays a critical role in the natural history of human plasma cell neoplasms (PCNs), such as plasma cell myeloma and plasmacytoma (PCT). IL-6 is also at the center of neoplastic plasma cell transformation in BALB/c (C) mice carrying a transgene, H2-L(d)-IL6, that encodes human IL-6 under control of the major histocompatibility complex H2-L(d) promoter: strain C.H2-L(d)-IL6. These mice are prone to PCT, but tumor development is incomplete with long latencies ( approximately 40% PCT at 12 months of age). To generate a more robust mouse model of IL-6-dependent PCN, we intercrossed strain C.H2-L(d)-IL6 with strains C.iMyc(Emu) or C.iMyc(Calpha), 2 interrelated gene-insertion models of the chromosomal T(12;15) translocation causing deregulated expression of Myc in mouse PCT. Deregulation of MYC is also a prominent feature of human PCN. We found that double-transgenic C.H2-L(d)-IL6/iMyc(Emu) and C.H2-L(d)-IL6/iMyc(Calpha) mice develop PCT with full penetrance (100% tumor incidence) and short latencies (3-6 months). The mouse tumors mimic molecular hallmarks of their human tumor counterparts, including elevated IL-6/Stat3/Bcl-X(L) signaling. The newly developed mouse strains may provide a good preclinical research tool for the design and testing of new approaches to target IL-6 in treatment and prevention of human PCNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.